알림·소식
알림·소식
[2019 Pasteur Colloquium] 신영근 교수, 충남대학교 약학대학
2019-10-01
____________________________________________
___________________________________________
*파스퇴르 콜로퀴엄 관련 문의사항은 sukyon.yang@ip-korea.org 로 이메일 송부 부탁드립니다. 연구소 관련 추가 내용은 홈페이지 (www.ip-korea.org) 를 통해 확인하실 수 있습니다.
** 한국파스퇴르연구소 약도: http://www.ip-korea.org/about_us/location.php
[한국파스퇴르연구소] 파스퇴르 콜로퀴엄
일시 : 2019년 10월 02일 (수), 오후 4시
장소 : 모노드 회의실 (1층), 한국파스퇴르연구소
______________________________________________________________________________________________________
.png)
연자
신영근 교수
충남대학교 약학대학
강연주제
How to Overcome High Clearance and Poor Bioavailability of New Chemical Entities during Lead Optimization? Strategies and Case Study
초록
Poor exposure following oral administration is a common challenge facing discovery programs and consequently a frequent focus for DMPK scientists. Frequently, potent compounds cannot be further developed due to less-than-ideal ADME (adsorption, distribution, metabolism and excretion) properties that prevent the compound to be available following oral administration. Beyond the discovery phase, the importance of understanding and optimizing oral exposure continues in the preclinical and ultimately clinical phase of drug development. Inadequate oral exposure could be due to suboptimal physicochemical properties, or problems in absorption from the gut, or first-pass metabolism in the gut and liver, or high intrinsic clearance of the compounds. The focus of this presentation is 1) to identify and learn about the issues that contribute to low oral exposure, and 2) to discuss approaches that one could use to overcome those challenges.
일시 : 2019년 10월 02일 (수), 오후 4시
장소 : 모노드 회의실 (1층), 한국파스퇴르연구소
______________________________________________________________________________________________________
연자
신영근 교수
충남대학교 약학대학
강연주제
How to Overcome High Clearance and Poor Bioavailability of New Chemical Entities during Lead Optimization? Strategies and Case Study
초록
Poor exposure following oral administration is a common challenge facing discovery programs and consequently a frequent focus for DMPK scientists. Frequently, potent compounds cannot be further developed due to less-than-ideal ADME (adsorption, distribution, metabolism and excretion) properties that prevent the compound to be available following oral administration. Beyond the discovery phase, the importance of understanding and optimizing oral exposure continues in the preclinical and ultimately clinical phase of drug development. Inadequate oral exposure could be due to suboptimal physicochemical properties, or problems in absorption from the gut, or first-pass metabolism in the gut and liver, or high intrinsic clearance of the compounds. The focus of this presentation is 1) to identify and learn about the issues that contribute to low oral exposure, and 2) to discuss approaches that one could use to overcome those challenges.
___________________________________________
*파스퇴르 콜로퀴엄 관련 문의사항은 sukyon.yang@ip-korea.org 로 이메일 송부 부탁드립니다. 연구소 관련 추가 내용은 홈페이지 (www.ip-korea.org) 를 통해 확인하실 수 있습니다.
** 한국파스퇴르연구소 약도: http://www.ip-korea.org/about_us/location.php